| Alzheimer's Disease
Leqembi vs Namzaric
Side-by-side clinical, coverage, and cost comparison for alzheimer's disease.Deep comparison between: Leqembi vs Namzaric with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNamzaric has a higher rate of injection site reactions vs Leqembi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Namzaric but not Leqembi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Leqembi
Namzaric
At A Glance
IV infusion
Every 2 weeks
Anti-amyloid beta antibody
Oral
Once daily
NMDA antagonist / AChE inhibitor
Indications
- Alzheimer's Disease
- Alzheimer's Disease
Dosing
Alzheimer's Disease Starting dosage: 10 mg/kg IV infusion once every 2 weeks over approximately one hour; maintenance dosage: 10 mg/kg IV infusion once every 4 weeks or 360 mg SC injection once weekly via autoinjector.
Alzheimer's Disease Recommended starting dose 7 mg/10 mg once daily in the evening; increase in 7 mg increments at minimum weekly intervals to maintenance dose of 28 mg/10 mg once daily in the evening.
Alzheimer's Disease, Severe Renal Impairment Recommended maintenance dose is 14 mg/10 mg once daily in the evening for patients with severe renal impairment (creatinine clearance 5-29 mL/min).
Contraindications
- Serious hypersensitivity to lecanemab-irmb or any excipient of LEQEMBI or LEQEMBI IQLIK (reactions include angioedema and anaphylaxis)
- Known hypersensitivity to memantine hydrochloride, donepezil hydrochloride, piperidine derivatives, or any excipient in the formulation
Adverse Reactions
Most common (>=5%) Infusion-related reactions, ARIA-H, ARIA-E, headache, superficial siderosis of CNS, rash, nausea/vomiting, cough, diarrhea
Serious Amyloid related imaging abnormalities (ARIA-E, ARIA-H), hypersensitivity reactions, infusion-related reactions
Most common (>=5%) Headache, diarrhea, dizziness (memantine); diarrhea, anorexia, vomiting, nausea, ecchymosis (donepezil, severe AD); insomnia, muscle cramp, fatigue (donepezil, mild to moderate AD).
Serious Cardiovascular conditions, peptic ulcer disease, gastrointestinal bleeding, nausea and vomiting, genitourinary conditions, seizures, pulmonary conditions.
Postmarketing Memantine: acute renal failure, agranulocytosis, congestive cardiac failure, hepatitis, leukopenia, pancreatitis, pancytopenia, Stevens-Johnson syndrome, suicidal ideation, thrombocytopenia, thrombotic thrombocytopenic purpura. Donepezil: abdominal pain, agitation, cholecystitis, confusion, convulsions, hallucinations, heart block, hemolytic anemia, hepatitis, hyponatremia, neuroleptic malignant syndrome, pancreatitis, rash.
Pharmacology
Lecanemab-irmb is a humanized IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta, reducing amyloid beta plaques in the brain - a defining pathophysiological feature of Alzheimer's disease.
NAMZARIC combines memantine, a low to moderate affinity uncompetitive NMDA receptor antagonist that blocks excessive glutamatergic activity, and donepezil, a reversible acetylcholinesterase inhibitor that increases central cholinergic transmission by inhibiting hydrolysis of acetylcholine; each component addresses a distinct postulated pathophysiological mechanism in Alzheimer's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Leqembi
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Namzaric
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Leqembi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Namzaric
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Leqembi
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Namzaric
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Leqembi Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Namzaric.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LeqembiView full Leqembi profile
NamzaricView full Namzaric profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.